CALA vs. NAVB, EVLO, CMRA, GNCAQ, GNCA, ARDS, STAB, EFTR, AMPE, and PXMD
Should you be buying Calithera Biosciences stock or one of its competitors? The main competitors of Calithera Biosciences include Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), eFFECTOR Therapeutics (EFTR), Ampio Pharmaceuticals (AMPE), and PaxMedica (PXMD). These companies are all part of the "pharmaceutical products" industry.
Calithera Biosciences vs.
Navidea Biopharmaceuticals (NYSE:NAVB) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings.
Calithera Biosciences received 341 more outperform votes than Navidea Biopharmaceuticals when rated by MarketBeat users. Likewise, 55.72% of users gave Calithera Biosciences an outperform vote while only 0.00% of users gave Navidea Biopharmaceuticals an outperform vote.
Navidea Biopharmaceuticals has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of -0.6, meaning that its share price is 160% less volatile than the S&P 500.
Navidea Biopharmaceuticals has higher revenue and earnings than Calithera Biosciences.
0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Comparatively, 6.6% of Calithera Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Navidea Biopharmaceuticals and Navidea Biopharmaceuticals both had 1 articles in the media. Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.
Summary
Navidea Biopharmaceuticals beats Calithera Biosciences on 5 of the 7 factors compared between the two stocks.
Get Calithera Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Calithera Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:CALA) was last updated on 3/29/2025 by MarketBeat.com Staff
Buy CALA Stock Free CALA Stock Alerts